Interestingly, a recent multidatabase cohort study has reported that treatment with CTLA-4-Ig was associated with a modestly reduced cardiovascular risk compared with tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients with diabetes25. Here, CTLA4 is linked to rheumatoid arthritis.